Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply squeeze on Novo Nordisk’s diabetes and obesity counterpa | The FDA has officially declared an end to the supply squeeze on Novo Nordisk’s GLP-1 drug semaglutide for diabetes and obesity in the U.

All doses of Novo's diabetes treatment Ozempic and weight-loss drug Wegovy were listed as available on the FDA's website in October, but the treatments were not taken off the offi

The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S. Food and Drug Administration (FDA).

Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared Friday. Why it matters: That's good news for Novo Nordisk (whose stock rose 5% Friday) and potentially bad news for Hims & Hers (which fell 26%).

The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug semaglutide, threatening the ability for compounding pharmacies to make copies of Ozempic and Wegovy.